Chlorambucil and cyclosporine A in Brazilian patients with Behçet's disease uveitis: a retrospective study

Zaghetto, Juliana Marques; Yamamoto, Mirian Mina; Souza, Murilo Barreto; Silva, Felipe Theodoro Bezerra Gaspar Carvalho da; Hirata, Carlos Eduardo; Olivalves, Edilberto; Yamamoto, Joyce Hisae

doi:10.1590/s0004-27492010000100007

Cited by 23 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kitaichi et al [27], in a multicentric study evaluating 44 patients, found panuveitis in 89.9% of females and 95.4% of males. In the study by Zaguetto et al [28], comprising 22 patients, 69.6% showed panuveitis and 52.3%, retinal vasculitis. Tugal-Tutkunt et al [26] studied 880 patients and reported 60.2% with panuveitis and 89% with retinal vasculitis, demonstrating a higher number of retinal vasculitis when compared with the study of 520 patients by el Belhadji et al [29], with prevalence of 37% of panuveitis, followed by 36.3% of anterior uveitis and 37% of retinal vasculitis.…”

Section: Discussionmentioning

confidence: 92%

Behçet’s disease in Brazilian patients: demographic and clinical features

et al. 2011

View full text Add to dashboard Cite

The aim of this study was to determine the demographic and clinical characteristics in patients diagnosed with Behçet's disease (BD) in Brazil. We performed a retrospective review of all the patients' records with BD diagnosed from 1988 to 2010 in the Rheumatology Department at the State University of Campinas (UNICAMP). All patients had to fulfill the International Study Group for Behçet's disease diagnostic criteria. Eighty-seven patients were included in the study. The female/male ratio was 1.18:1, and the mean age at the onset of the disease onset was 28.03 ± 7.57 years. Oral aphthosis was the most frequent manifestation (100%). Genital aphthosis was also frequent (77%), followed by pseudofolliculitis (47.67%). Ocular symptoms were present in 80% and neurological manifestations in 31.03% of the patients. Arthralgia was reported in 31.03% and arthritis in 13.79% of the cases. Vascular involvement was seen in 13.95% of the patients. Only 1.14% had gastrointestinal involvement. This series, from a South American country, showed a similar general pattern of the BD to those found in different endemic areas in the world, with a high frequency of ocular and neurological manifestations.

show abstract

Section: Discussionmentioning

confidence: 92%

Behçet’s disease in Brazilian patients: demographic and clinical features

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Moreover, in patients who did achieve control, some required >10 mg/ day of prednisone or its equivalent to achieve that goal 1,[17][18][19][20][21] -this despite the generally held view by such specialists that an acceptable maintenance dose of oral prednisone is below 10 mg/day. 32 While the cause of such partial patient responses is clearly complex and undoubtedly includes incomplete individual responses to the specific agents and approaches used in the various studies, including relative resistance to corticosteroids, 33 perhaps we should all give more consideration to other less generally used options for treating patients with chronic sight-threatening uveitis, such as short-term, high-dose chlorambucil [34][35][36] and systemic interferon therapy, 37,38 both of which, like cyclophosphamide, appear to offer the possibility of drug-free remission.…”

Section: E T Cunningham Et Almentioning

confidence: 99%

Uveitis Treatment Trials—A Cross-study Perspective

Cunningham¹,

Goldstein²,

Zierhut³

2012

Ocular Immunology and Inflammation

View full text Add to dashboard Cite

“…Furthermore, the other important reason to use biologicals is the often poor visual outcome after immunomodulatory therapy. Visual acuity might be lower than 0.1 after 5–10 years of follow‐up (Zaghetto et al. 2010; Whitcup et al.…”

Section: Introductionmentioning

confidence: 99%

Light on the Horizont: biologicals in Behçet uveitis

Hazırolan

Stübiger

Pleyer

2012

Acta Ophthalmologica

View full text Add to dashboard Cite

Relapsing ocular involvement is one of the major manifestations in Behçet disease (BD). When ocular BD is left untreated, it often results in blindness in <5 years. Combining systemic corticosteroids with cyclosporine A and other conventional immune modulating agents has been the only choice for treatment. More recently, the introduction of 'biologics' seems to be an effective therapy in patients affected with BD, especially in those with ocular disease. Our purpose was to survey the current knowledge regarding the biological therapeutic approaches for Behçet uveitis. We focused on the most commonly used biological agents: 'tumor necrosis factor-alpha antagonists' and 'interferon alpha'. We attempted to compare the effectiveness of these two biologicals and tried to balance on the pros and cons of these agents in clinical practice. The impressive efficacy of both approaches in sight-threatening BD argues for their expanding role. Earlier introduction of these agents in the course of disease may prevent irreversible structural damage and may result in improved long-term prognosis.

show abstract

Chlorambucil and cyclosporine A in Brazilian patients with Behçet's disease uveitis: a retrospective study

Cited by 23 publications

References 22 publications

Behçet’s disease in Brazilian patients: demographic and clinical features

Behçet’s disease in Brazilian patients: demographic and clinical features

Uveitis Treatment Trials—A Cross-study Perspective

Light on the Horizont: biologicals in Behçet uveitis

Contact Info

Product

Resources

About